We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Acute Sleep Loss Triggers Increase in Plasma Levels of Tau Protein in Young Adults

By LabMedica International staff writers
Posted on 20 Jan 2020
Print article
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
Image: Abnormal accumulation of tau protein in neuronal cell bodies (arrow) and neuronal extensions (arrowhead) in the neocortex of a patient who had died with Alzheimer's disease (Photo courtesy of Wikimedia Commons)
A team of Swedish researchers has found that acute sleep loss results in increased blood levels of t-tau protein, a key biomarker for nervous system disorders such as Alzheimer’s disease.

Previous studies had shown that disrupted sleep increased CSF (cerebrospinal fluid) levels of tau and beta-amyloid (ABeta) and was associated with an increased risk of Alzheimer’s disease (AD). The aim of the current study, conducted by investigators at Uppsala University (Sweden), was to determine whether acute sleep loss altered diurnal profiles of plasma-based AD-associated biomarkers.

The current study involved 15 healthy, normal-weight men with an average age of 22 years. The design of the experiment comprised two phases. For each phase, the subjects were housed in a sleep clinic for two days and nights under a strict meal and activity schedule. Blood samples were collected in the evening and again in the morning. For one phase, participants were allowed an uninterrupted night of sleep both nights. For the other phase, participants were allowed uninterrupted sleep the first night followed by a second night of sleep deprivation.

Plasma levels of total tau (t-tau), ABeta40, ABeta42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in the blood samples were assessed using ultrasensitive single molecule array assays or ELISAs,

Results revealed the after sleep deprivation, the subjects had an average 17% increase in tau levels in their blood. In contrast, following a night of interrupted sleep, the subjects had an average increase in tau levels of only 2%. No changes between the sleep conditions were seen for levels of ABeta40, ABeta42, NfL, or GFAP.

"Many of us experience sleep deprivation at some point in our lives due to jet lag, pulling an all-nighter to complete a project, or because of shift work, working overnights. or inconsistent hours," said senior author Dr. Jonathan Cedernaes, a senior researcher at Uppsala University. "Our exploratory study shows that even in young, healthy individuals, missing one night of sleep results in a slight increase in the level of tau in blood. This suggests that over time, similar types of sleep disruption could potentially have detrimental effects."

"It is important to note that while accumulation of tau in the brain is not good, in the context of sleep loss, we do not know what higher levels of tau in blood represent" said Dr. Cedernaes. "When neurons are active, release of tau in the brain is increased. Higher levels in the blood may reflect that these tau proteins are being cleared from the brain or they may reflect an overall elevation of the concentration of tau levels in the brain. Future studies are needed to investigate this further, as well as to determine how long these changes in tau last, and to determine whether changes in tau in blood reflects a mechanism by which recurrent exposure to restricted, disrupted or irregular sleep may increase the risk of dementia. Such studies could provide key insight into whether interventions targeting sleep should begin at an early age to reduce a person's risk of developing dementia or Alzheimer's disease."

The study was published in the January 8, 2020, online edition of the journal Neurology.

Related Links:
Uppsala University

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.